hydroxyurea,revumenib
syndax pharma
['revumenib', 'leusm', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'hydroxyurea', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)']
#ash22 #leusm issa: revumenib median time to resp 1.9m, median dor 9.1 in cr/crh. median os overall 7mos. differentiation syndrome seen at median onset 14d. revumenib downregs flt3 txn, putatively via meis1 (may be relevant to combo therapy w flt3i?), with 66% orr in kmt2ar/flt3m 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)